- Home
- PBH vs VKTX Comparison
PBH vs VKTX Comparison
Compare PBH & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBH
- VKTX
- Stock Information
- Founded
- PBH 1996
- VKTX 2012
- Country
- PBH United States
- VKTX United States
- Employees
- PBH N/A
- VKTX N/A
- Industry
- PBH Biotechnology: Pharmaceutical Preparations
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- PBH Health Care
- VKTX Health Care
- Exchange
- PBH Nasdaq
- VKTX Nasdaq
- Market Cap
- PBH 3.8B
- VKTX 3.5B
- IPO Year
- PBH 2005
- VKTX 2015
- Fundamental
- Price
- PBH $74.98
- VKTX $31.88
- Analyst Decision
- PBH Buy
- VKTX Strong Buy
- Analyst Count
- PBH 5
- VKTX 13
- Target Price
- PBH $94.00
- VKTX $86.92
- AVG Volume (30 Days)
- PBH 411.5K
- VKTX 3.7M
- Earning Date
- PBH 08-07-2025
- VKTX 07-23-2025
- Dividend Yield
- PBH N/A
- VKTX N/A
- EPS Growth
- PBH 2.88
- VKTX N/A
- EPS
- PBH 4.29
- VKTX N/A
- Revenue
- PBH $1,137,762,000.00
- VKTX N/A
- Revenue This Year
- PBH $2.04
- VKTX N/A
- Revenue Next Year
- PBH $2.07
- VKTX $338.60
- P/E Ratio
- PBH $17.52
- VKTX N/A
- Revenue Growth
- PBH 1.10
- VKTX N/A
- 52 Week Low
- PBH $64.94
- VKTX $18.92
- 52 Week High
- PBH $90.04
- VKTX $81.73
- Technical
- Relative Strength Index (RSI)
- PBH 31.53
- VKTX 51.30
- Support Level
- PBH $72.53
- VKTX $31.80
- Resistance Level
- PBH $74.45
- VKTX $34.73
- Average True Range (ATR)
- PBH 1.31
- VKTX 1.90
- MACD
- PBH 0.04
- VKTX -0.18
- Stochastic Oscillator
- PBH 29.67
- VKTX 15.85
About PBH Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.